Navigation Links
European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
Date:5/14/2012

LONDON, May 14, 2012 /PRNewswire/ -- The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement. However, the launch of three blockbuster oral anticoagulants is projected to help the thrombosis therapeutics market address these challenges. It is also anticipated to help companies tackle competition from low cost generics. 

New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Thrombosis Therapeutics Market, finds that the market earned revenues of approximately $8.67 billion in 2010 and estimates this to reach approximately $13.01 billion in 2017 at a compound annual growth rate (CAGR) of 6.6 per cent from 2010-2017.

"The rising number of people suffering from thrombosis is resulting in higher demand for related therapeutics," notes Frost & Sullivan Research Analyst Deepika Pramod Chopda. "This, coupled with strong pipeline development, is pushing robust growth in the overall market."

About 4.5 million people in Europe are diagnosed with thrombosis annually, underlining the growing incidence of the disease. The result has been higher demand for treatment, complementing overall market growth. Approximately $3.46 billion was spent on R&D, indicative of vigorous efforts to develop innovative thrombotic drugs.

A key challenge has been the competition from generic manufacturers that are able to offer cost-effective equivalents to patented brands.

"The loss of patent rights of established thrombosis drugs in the early stages of the forecast period will contribute to the rise of generics," explains Deepika. "These low cost substitutes are likely to hinder the adoption of new and improved products."

Stringent approval procedures are also hampering market expansion. The European Medicines Agency (EMA) assesses several factors at every level of a drug's progress. This rigorous process limits the number of new medicines entering the market.

"Awareness raising through public healthcare forums and organisations about new developments and innovative treatment options will contribute towards establishing greater end-user confidence," concludes Deepika. "In the meantime, precautionary measures like adopting healthy lifestyle practices will help limit the incidence of the disease."

If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at janique.morvan@frost.com.

Analysis of the European Thrombosis Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market, Generic Pharmaceuticals Market – A Global Analysis and European Pharmaceutical and Biotech Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Analysis of the European Thrombosis Therapeutics Market
M74C-52

Contact:
Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42
E: janique.morvan@frost.com

http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Lipitor® in Five European Countries
2. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
5. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
6. Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
7. Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries
8. Dune Medical Devices Hosts Symposium Featuring MarginProbe® System at European Breast Cancer Conference
9. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
10. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
11. BioStorage Technologies Integrates Sample Preparation Services into European Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- Fotona, based in the U.S. and Europe ... Lightwalker dental laser at the upcoming 151 st Midwinter ... in booth #4815. The ST PRO is a full featured ... features of the award winning, industry leading Lightwalker ATS. At an ... be very attractive to many dentists hesitating to incorporate lasers ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today ... and full year ended December 31, 2015. ... transformational year for Vanda with the continued growth of ... of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., ... our U.S. product portfolio builds on this success and ...
(Date:2/10/2016)... 2016 A new report from business intelligence provider GBI ... the Alzheimer,s disease market will more than double from just under $5 billion ... Growth Rate (CAGR) of 11%. Canada , ... Spain , the UK, and Japan , ... --> Canada , France , ...
Breaking Medicine Technology:
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... Best Water Brand. There were three leading bottled water brand owners that topped the ... services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):